Subscribe to our Newsletters !!

    Pharma

    Keeping Your Chemical Facility Updated: Ways To Improve Maintenance

    The chemical industry has been one of the leading sectors in industrial automation for years, where more and more complex systems are being brought together that are allowing to highly improve competitiveness. All this in an environment where safety and environmental regulations are among the most demanding. Therein lies the value of turning maintenance into

    Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats

    March 23, 2021, MUMBAI – Cipla Therapeutics, an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as “Cipla”) and SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly

    Cipla Enters into a Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India

    Mumbai, India, May 10, 2021: Cipla Limited (BSE: 500087 | NSE: CIPLA EQ, hereafter referred to as “Cipla”) today announced it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company, USA for the manufacture and commercialization of the drug baricitinib for Covid-19 indication. Baricitinib was issued a restricted emergency use approval

    Alembic Pharma gets USFDA gesture for bipolar depression drug

    New Delhi, May 14 (PTI) Drug firm Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for Lurasidone Hydrochloride tablets, used to treat bipolar depression. The approved product is therapeutically equivalent to the reference listed drug product (RLD) Latuda tablets of Sunovion Pharmaceuticals Inc. The company has received approval

    Cipla launches ‘ViraGen’ a polymerase chain reaction (Covid-19 RT-PCR) test

    Mumbai, India; May 20 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd. ViraGen is Cipla’s third offering in the Covid-19 testing segment. Cipla already has partnerships

    Glenmark Pharma gets last gesture from USFDA for Theophylline ER tablets

    Glenmark Pharma on Friday said it has received final approval from the US health regulator for Theophylline extended-release (ER) tablets. Theophylline extended-release tablets are used to prevent and treat wheezing, shortness of breath, and chest tightness caused by asthma, chronic bronchitis, emphysema, and other lung diseases. In a regulatory filing Glenmark Pharmaceuticals said it has

    Nicotine: Smoking out the truth

    Humanity has had a tumultuous history with nicotine, with use of nicotine-rich tobacco for ceremonial and social functions starting as early as 1400 BC, before being introduced to Europe as a medicinal item in the 16th century. In the last hundred years nicotine reached peak popularity, as tobacco use was glamorised through cigarettes, and then

    Xuanzhu and SignalChem Lifesciences Corporation Announce Collaboration and Licensing Agreement for SLC-391 in the Greater China Region

    September 27, 2021 – Beijing, China and Richmond, British Columbia, Canada – Life Science Newswire – Sihuan Pharmaceutical Holdings Group Ltd., together with its subsidiaries and SignalChem Lifesciences Corporation today announced that Sihuan Pharmaceutical Holdings Group Ltd subsidiary company Xuanzhu Biopharmaceutical Co., Ltd. (“Xuanzhu”) and SignalChem Lifesciences Corporation (“SignalChem”) have entered into an exclusive collaboration

    Alembic Pharmaceuticals receives USFDA Tentative Approval for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg.

    7th January, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Vortioxetine Tablets 5 mg, 10 mg, 15 mg, and 20 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug